Information  X 
Enter a valid email address

Venn Life Sciences (ORPH)

  Print      Mail a friend

Thursday 27 June, 2019

Venn Life Sciences

Result of General Meeting

RNS Number : 6658D
Venn Life Sciences Holdings PLC
27 June 2019

27 June 2019

Venn Life Sciences Holdings Plc

("Venn Life Sciences" or the "Company")

Result of General Meeting

Venn Life Sciences is pleased to announce that at the Company's General Meeting held earlier today in relation to the Company's proposed acquisition of Open Orphan and connected Placing, all of the Resolutions put to the meeting were duly passed.

The Board is pleased to note that each Resolution was unanimously passed by Shareholders. The Board is excited by the growth potential of the Enlarged Group following completion of the Proposals and looks forward to updating Shareholders on the Company's progress going forward.

Director Appointment

As announced on 10 May 2019 and described in the Company's admission document dated 11 June 2019 ("Admission Document"), Dr Maurice Treacy will be appointed as an Executive Director of the Company with effect from Admission.

Admission and Change of Name

Application has been made for the admission of the Enlarged Share Capital to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 28 June 2019.

The change of name of the Company to Open Orphan plc is expected to take effect later today and the change of TIDM to "ORPH" is expected to take effect from Admission.

Total voting rights

Following Admission, the total number of ordinary shares of 0.1 pence each ("Ordinary Shares") in issue with voting rights will be 253,493,259 Ordinary Shares and Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined, capitalised terms used in this announcement are as defined in the Admission Document.


Venn Life Sciences Holdings Plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Advisor and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

About Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn Life Sciences has dedicated operations in France, Germany, the Netherlands, the UK and Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences

Venn Life Sciences: [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t